ESPRHealthcareSmall-Cap

Esperion Therapeutics, Inc. Insider Trading Activity

Every SEC Form 4 insider transaction reported for Esperion Therapeutics, Inc. (ESPR), sourced directly from SEC EDGAR and updated as new filings are accepted.

Last updated:

Quick Answer

Are ESPR insiders buying or selling?

Esperion Therapeutics, Inc. insiders reported 35 open-market buys ($56.0M) and 75 sells ($11.2M) across 110 Form 4 filings — a net buying position of $44.8M.

Source: SEC EDGAR Form 4

Key Statistics (as of Jun 18, 2026)

Total Form 4 filings
110
SEC EDGAR
Insider filers
13
Insider buys (35)
$56.0M
Insider sells (75)
$11.2M

Insider sentiment

Net buying

Net insider flow of $44.8M in net buying.

Recent ESPR insider transactions

DateInsiderRoleTypeSharesPriceValue
Jun 18, 2026Benjamin LookerChief Legal OfficerSale11.8K$3.16$37.3K
Jun 18, 2026Sheldon L. KoenigPresident and CEOSale53.6K$3.16$169.1K
Jun 18, 2026Benjamin HalladayChief Financial OfficerSale10.8K$3.16$34.0K
Mar 18, 2026Benjamin LookerChief Legal OfficerSale5.7K$2.70$15.4K
Mar 18, 2026Sheldon L. KoenigPresident and CEOSale25.6K$2.72$69.5K
Mar 18, 2026Benjamin HalladayChief Financial OfficerSale6.4K$2.71$17.4K
Jan 21, 2026Benjamin LookerGeneral CounselSale1.7K$2.88$4.9K
Dec 18, 2025Sheldon L. KoenigPresident and CEOSale48.2K$3.67$177.2K
Dec 18, 2025Benjamin HalladayChief Financial OfficerSale7.3K$3.67$26.9K
Dec 18, 2025Benjamin LookerGeneral CounselSale6.5K$3.67$23.9K
Oct 20, 2025Benjamin LookerGeneral CounselSale1.2K$2.62$3.3K
Sep 18, 2025Benjamin LookerGeneral CounselSale6.3K$2.80$17.6K
Sep 18, 2025Sheldon L. KoenigPresident and CEOSale28.4K$2.79$79.3K
Sep 18, 2025Benjamin HalladayChief Financial OfficerSale7.0K$2.81$19.8K
Jul 18, 2025Benjamin LookerGeneral CounselSale1.3K$1.13$1.5K
Jul 18, 2025Benjamin HalladayChief Financial OfficerSale11$1.12$12.27
Jun 18, 2025Benjamin LookerGeneral CounselSale6.4K$1.15$7.4K
Jun 18, 2025Sheldon L. KoenigPresident and CEOSale30.5K$1.11$33.8K
Jun 18, 2025Benjamin HalladayChief Financial OfficerSale7.2K$1.15$8.3K
Apr 21, 2025Eric WarrenChief Commercial OfficerSale108$0.98$105.62
Apr 21, 2025Benjamin HalladayChief Financial OfficerSale8$0.96$7.71
Mar 19, 2025Benjamin HalladayChief Financial OfficerSale3.5K$1.48$5.2K
Mar 19, 2025Eric WarrenChief Commercial OfficerSale2.4K$1.49$3.6K
Mar 19, 2025Sheldon L. KoenigPresident and CEOSale13.0K$1.50$19.6K
Feb 20, 2025Eric WarrenChief Commercial OfficerSale239$1.87$446.45

Showing the 25 most recent of 110 Form 4 filings for Esperion Therapeutics, Inc..

Most active ESPR insiders

  • Eric Warren27 filings
  • V N Biotech Target19 filings
  • Sheldon L. Koenig15 filings
  • Benjamin Halladay11 filings
  • Benjamin Looker10 filings

Ask anything about ESPR insider activity

Use Trabud's AI agent to query Esperion Therapeutics, Inc.'s Form 4 history in plain English — "Show me ESPR CEO purchases this year" or compare it against any other ticker.

Open the AI agent

ESPR insider trading FAQ

Are Esperion Therapeutics, Inc. insiders buying or selling?

Across 110 SEC Form 4 filings, Esperion Therapeutics, Inc. (ESPR) insiders reported 35 open-market purchases totaling $56.0M and 75 sales totaling $11.2M. That is a net buying position of $44.8M.

How many insiders trade ESPR stock?

13 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Esperion Therapeutics, Inc.. The most recent filing was accepted on Jun 18, 2026.

Where does Trabud get ESPR insider trading data?

All ESPR insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.

Looking for another company? Browse all tracked companies.

Related Content